esmo 2019: dr. ramalingam discusses confirmatory data in advanced nsclc
Published 4 years ago • 90 plays • Length 9:53Download video MP4
Download video MP3
Similar videos
-
1:43
dr. ramalingam discusses the results of the phase iii revel study in nsclc
-
1:19
dr. ramalingam on emerging combination regimens in nsclc
-
1:05
dr. ramalingam on the activity of osimertinib combinations in nsclc
-
2:04
dr. ramalingam discusses the utility of tecemotide in nsclc
-
2:04
dr. suresh ramalingam on frontline osimertinib data in egfr nsclc
-
1:40
dr. ramalingam on the role of osimertinib in egfr t790m-positive advanced nsclc
-
1:50
researcher comment: positive os data for osimertinib in flaura trial | suresh ramalingam
-
1:24
suresh ramalingam, md, fasco, shares results from the flaura trial presented at esmo 2019
-
13:04
esmo 2019: dr. spigel highlights progress in lung cancer
-
6:43
esmo 2018: dr. ramalingam shares insight on lung cancer studies
-
1:19
dr. ramalingam on the significance of the flaura trial in nsclc
-
2:09
dr. ramalingam on flaura trial results in egfr-mutant nsclc
-
13:06
noemi reguart, esmo 2019 - egfr tyrosine kinase inhibitors in nsclc
-
2:34
dr. ramalingam on flaura findings in egfr-mutant nsclc
-
8:55
suresh ramalingam: osimertinib vs comparator egfr-tki 1st-line in egfrm advanced nsclc (flaura)
-
8:44
flaura final analysis: osimertinib for first-line egfrm nsclc
-
2:15
dr. ramalingam on pembrolizumab and chemotherapy in nsclc
-
1:06
lung cancer highlights from esmo 2022
-
1:23
dr. suresh ramalingam explores cytotoxics in lung cancer